XAIR News and Press, Beyond Air Inc. From 02/22/23

GARDEN CITY, N.Y., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respi...

Beyond Air, Inc. (XAIR) Q3 2023 Earnings Conference Call February 9, 2023, 4:30 PM ET Company Participants Edward Barger - Head, Investor Relations Steve Lisi - Chairman and CEO Duncan Fatkin - Chief Commercial Officer Douglas Larson - Chief Financial Officer ...

Beyond Air press release ( NASDAQ: XAIR ): Q3 GAAP EPS of -$0.43 misses by $0.02 . As of December 31, 2022, the Company reported cash and cash equivalents, marketable securities, and restricted cash of $63.2 million. Total cash burn in the quarter ended December 31, 2022, ...

U.S. commercial launch continues for LungFit® PH for the treatment of term and near-term neonates with hypoxic respiratory failure Presented positive in vivo combination data with anti-PD1 that support the potential of the Company’s novel gaseous ultra-high concent...

Summary Investors are positioned with a bullish stance heading into Beyond Air, Inc.'s FY22 earnings. This indicates the market expects a strong set of numbers from the company, and has priced this into the stock. We have upsides to $8–$9 based on the market's positioning, wi...

Beyond Cancer an affiliate of Beyond Air ( NASDAQ: XAIR ) appoints Gavin Choy, PharmD as COO. He most recently served as Chief Clinical Development Officer at GT Biopharma. For further details see: Beyond cancer appoints Gavin Choy, as COO

GARDEN CITY, N.Y. and HAMILTON, Bermuda, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, announced today the appointment of Gavin Choy, P...

Dr. Dirbas, Associate Professor of Surgery at the Stanford School of Medicine will chair the Scientific Advisory Board (SAB) The new members join Sunil J. Panchal, MD on the Scientific Advisory Board GARDEN CITY, NY and HAMILTON, Bermuda, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Beyond C...

GARDEN CITY, N.Y., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pu...

GARDEN CITY, N.Y. and HAMILTON, Bermuda, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, announced today the publication of pre-clini...